Volume | 154,768 |
|
|||||
News | - | ||||||
Day High | 12.59 | Low High |
|||||
Day Low | 10.10 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cidara Therapeutics Inc | CDTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
10.18 | 10.10 | 12.59 | 12.35 | 10.25 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,218 | 154,768 | $ 11.10 | $ 1,718,668 | - | 10.004 - 29.60 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:23:01 | 5 | $ 14.66 | USD |
Cidara Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.05B | 90.43M | - | 64.29M | -29.8M | -0.33 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cidara Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CDTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 14.46 | 16.00 | 10.004 | 10.88 | 1,348,084 | 0.046 | 0.32% |
1 Month | 15.026 | 24.40 | 10.004 | 17.18 | 1,330,307 | -0.52 | -3.46% |
3 Months | 13.00 | 24.40 | 10.004 | 15.85 | 759,103 | 1.51 | 11.58% |
6 Months | 16.822 | 24.40 | 10.004 | 15.63 | 682,262 | -2.32 | -13.77% |
1 Year | 22.60 | 29.60 | 10.004 | 18.99 | 710,686 | -8.09 | -35.81% |
3 Years | 44.20 | 47.80 | 8.00 | 24.64 | 822,379 | -29.69 | -67.18% |
5 Years | 46.20 | 89.00 | 8.00 | 31.50 | 647,796 | -31.69 | -68.60% |
Cidara Therapeutics Description
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. |